Paclitaxel and Cisplatin with or without Cetuximab in metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label Phase II trial
Graphical abstract
Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma (ESCC) underscores the urgent need for identifying new treatment approaches for this challenging disease. We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC. In this randomized, multicenter, open-label, phase 2 clinical trial, patients were randomized to receive TP [paclitaxel (175 mg/m2 i.v. on day 1 of every 3-week cycle) and cisplatin (75 mg/m2 i.v. on day 1 of every 3-week cycle).
